{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,6]],"date-time":"2024-08-06T07:50:12Z","timestamp":1722930612517},"reference-count":52,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T00:00:00Z","timestamp":1395878400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":523,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Lab Hematology"],"published-print":{"date-parts":[[2014,12]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Therapeutic advances and the availability of novel agents have significantly improved outcomes in myeloma; yet, it remains incurable and strategies to improve survival continue to be sought. One approach is to prolong the duration of response and increase progression\u2010free survival (<jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>) through consolidation or maintenance treatment with regimens that have low toxicity profiles, and do not negatively impact on quality of life. Data from several studies with thalidomide, lenalidomide and bortezomib consistently show improvements in response and <jats:styled-content style=\"fixed-case\">PFS<\/jats:styled-content>, although results have still to be confirmed with respect to overall survival (<jats:styled-content style=\"fixed-case\">OS<\/jats:styled-content>). Despite the promising data, the optimal use of consolidation and maintenance treatment in terms of regimen, dose and duration has yet to be defined. Given the evidence to date, the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content> Myeloma Forum believes that both maintenance and consolidation therapy should be considered as treatment options for patients with myeloma. Patients should be encouraged to enrol in clinical studies. This document reviews the current position of maintenance and consolidation for patients with myeloma treated in the <jats:styled-content style=\"fixed-case\">UK<\/jats:styled-content>.<\/jats:p>","DOI":"10.1111\/ijlh.12205","type":"journal-article","created":{"date-parts":[[2014,3,27]],"date-time":"2014-03-27T06:11:04Z","timestamp":1395900664000},"page":"665-675","update-policy":"http:\/\/dx.doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["United Kingdom Myeloma Forum position statement on the use of consolidation and maintenance treatment in myeloma"],"prefix":"10.1111","volume":"36","author":[{"given":"N.","family":"Rabin","sequence":"first","affiliation":[{"name":"Department of Haematology University College London Hospitals London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Lai","sequence":"additional","affiliation":[{"name":"Myeloma UK Edinburgh UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Pratt","sequence":"additional","affiliation":[{"name":"Department of Haematology Birmingham Hertlands Hospital Birmingham UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Morgan","sequence":"additional","affiliation":[{"name":"Haemato\u2010oncology Royal Marsden Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Snowden","sequence":"additional","affiliation":[{"name":"Department of Haematology Sheffield Teaching Hospitals Sheffield UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Bird","sequence":"additional","affiliation":[{"name":"Department of Haematology University Hospitals Bristol Bristol UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Cook","sequence":"additional","affiliation":[{"name":"St James's Institute of Oncology Leeds Teaching Hospitals Trust Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Bowcock","sequence":"additional","affiliation":[{"name":"Department of Haematology Princess Royal Hospital Orpington Kent UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Owen","sequence":"additional","affiliation":[{"name":"St James's Institute of Oncology Leeds Teaching Hospitals Trust Leeds UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Yong","sequence":"additional","affiliation":[{"name":"Department of Haematology University College London Hospitals London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Wechalaker","sequence":"additional","affiliation":[{"name":"Centre for Amyloidosis and Acute Phase Proteins Royal Free Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Low","sequence":"additional","affiliation":[{"name":"Myeloma UK Edinburgh UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F.","family":"Davies","sequence":"additional","affiliation":[{"name":"Haemato\u2010oncology Royal Marsden Hospital London UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the United Kingdom Myeloma Forum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2014,3,27]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_5_2_1","DOI":"10.1182\/blood-2007-08-104984"},{"doi-asserted-by":"publisher","key":"e_1_2_5_3_1","DOI":"10.1182\/blood-2007-10-116129"},{"doi-asserted-by":"publisher","key":"e_1_2_5_4_1","DOI":"10.1200\/JCO.2009.25.4177"},{"key":"e_1_2_5_5_1","first-page":"656","volume-title":"Harrison's Principles of Internal Medicine","author":"Longo D","year":"2004"},{"doi-asserted-by":"publisher","key":"e_1_2_5_6_1","DOI":"10.4065\/79.7.867"},{"doi-asserted-by":"publisher","key":"e_1_2_5_7_1","DOI":"10.1056\/NEJMra1011442"},{"doi-asserted-by":"publisher","key":"e_1_2_5_8_1","DOI":"10.1182\/blood-2009-03-201053"},{"doi-asserted-by":"publisher","key":"e_1_2_5_9_1","DOI":"10.1200\/JCO.2009.25.4250"},{"doi-asserted-by":"publisher","key":"e_1_2_5_10_1","DOI":"10.1200\/JCO.2012.46.2119"},{"doi-asserted-by":"publisher","key":"e_1_2_5_11_1","DOI":"10.1182\/blood-2008-05-159624"},{"doi-asserted-by":"publisher","key":"e_1_2_5_12_1","DOI":"10.1038\/bjc.1988.17"},{"doi-asserted-by":"publisher","key":"e_1_2_5_13_1","DOI":"10.1056\/NEJM199005173222005"},{"doi-asserted-by":"publisher","key":"e_1_2_5_14_1","DOI":"10.1023\/A:1026548226770"},{"doi-asserted-by":"publisher","key":"e_1_2_5_15_1","DOI":"10.1046\/j.1365-2141.2001.02857.x"},{"doi-asserted-by":"publisher","key":"e_1_2_5_16_1","DOI":"10.1182\/blood.V99.9.3163"},{"doi-asserted-by":"publisher","key":"e_1_2_5_17_1","DOI":"10.1056\/NEJMoa053583"},{"doi-asserted-by":"publisher","key":"e_1_2_5_18_1","DOI":"10.1182\/blood-2006-05-022962"},{"doi-asserted-by":"publisher","key":"e_1_2_5_19_1","DOI":"10.1182\/blood-2009-05-222539"},{"doi-asserted-by":"publisher","key":"e_1_2_5_20_1","DOI":"10.1182\/blood-2011-06-357038"},{"doi-asserted-by":"publisher","key":"e_1_2_5_21_1","DOI":"10.1002\/ajh.23274"},{"doi-asserted-by":"publisher","key":"e_1_2_5_22_1","DOI":"10.1182\/blood-2012-09-451872"},{"doi-asserted-by":"publisher","key":"e_1_2_5_23_1","DOI":"10.1016\/j.leukres.2012.04.001"},{"key":"e_1_2_5_24_1","first-page":"S7","article-title":"Experience from the MRC Myeloma IX study","volume":"13","author":"Child JA","year":"2013","journal-title":"Clin Lymphoma Myeloma Leuk"},{"doi-asserted-by":"publisher","key":"e_1_2_5_25_1","DOI":"10.1158\/1078-0432.CCR-12-3211"},{"doi-asserted-by":"publisher","key":"e_1_2_5_26_1","DOI":"10.1182\/blood-2008-03-145235"},{"doi-asserted-by":"publisher","key":"e_1_2_5_27_1","DOI":"10.1182\/blood-2012-05-432203"},{"doi-asserted-by":"publisher","key":"e_1_2_5_28_1","DOI":"10.3109\/10428194.2012.760736"},{"doi-asserted-by":"publisher","key":"e_1_2_5_29_1","DOI":"10.1016\/S0140-6736(06)68338-4"},{"doi-asserted-by":"publisher","key":"e_1_2_5_30_1","DOI":"10.1200\/JCO.2009.26.1610"},{"doi-asserted-by":"publisher","key":"e_1_2_5_31_1","DOI":"10.1182\/blood-2009-08-237974"},{"doi-asserted-by":"publisher","key":"e_1_2_5_32_1","DOI":"10.3324\/haematol.2009.020586"},{"doi-asserted-by":"publisher","key":"e_1_2_5_33_1","DOI":"10.1007\/s00277-011-1224-1"},{"doi-asserted-by":"publisher","key":"e_1_2_5_34_1","DOI":"10.1200\/JCO.2008.18.8573"},{"doi-asserted-by":"publisher","key":"e_1_2_5_35_1","DOI":"10.1111\/j.1365-2141.2012.09188.x"},{"doi-asserted-by":"publisher","key":"e_1_2_5_36_1","DOI":"10.1200\/JCO.2009.22.7561"},{"doi-asserted-by":"publisher","key":"e_1_2_5_37_1","DOI":"10.1056\/NEJMoa1114083"},{"doi-asserted-by":"publisher","key":"e_1_2_5_38_1","DOI":"10.1056\/NEJMoa1114138"},{"doi-asserted-by":"publisher","key":"e_1_2_5_39_1","DOI":"10.1056\/NEJMoa1112704"},{"key":"e_1_2_5_40_1","article-title":"Melphalan\/prednisone, lenalidomide (MPR) versus high\u2010dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients","volume":"31","author":"Boccadero M","year":"2013","journal-title":"J Clin Oncol"},{"doi-asserted-by":"publisher","key":"e_1_2_5_41_1","DOI":"10.1016\/S1470-2045(11)70081-X"},{"key":"e_1_2_5_42_1","first-page":"S31","article-title":"Improved progression free survival with bortezomib consolidation after high dose melphalan: results of a randomised phase III trial","volume":"96","author":"Mellqvist UH","year":"2011","journal-title":"Haematologica"},{"doi-asserted-by":"publisher","key":"e_1_2_5_43_1","DOI":"10.1200\/JCO.2009.23.7172"},{"doi-asserted-by":"publisher","key":"e_1_2_5_44_1","DOI":"10.1182\/blood-2012-02-408898"},{"doi-asserted-by":"publisher","key":"e_1_2_5_45_1","DOI":"10.1200\/JCO.2011.39.6820"},{"doi-asserted-by":"publisher","key":"e_1_2_5_46_1","DOI":"10.1182\/blood-2012-02-408922"},{"doi-asserted-by":"publisher","key":"e_1_2_5_47_1","DOI":"10.1182\/blood-2012-05-427815"},{"doi-asserted-by":"publisher","key":"e_1_2_5_48_1","DOI":"10.1200\/JCO.2010.29.8216"},{"doi-asserted-by":"publisher","key":"e_1_2_5_49_1","DOI":"10.1016\/S0145-2126(12)70007-3"},{"key":"e_1_2_5_50_1","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2013.31.15_suppl.8517","article-title":"Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): meta\u2010analysis of 6,383 individual patient data (IPD)","volume":"31","author":"Palumbo A","year":"2013","journal-title":"J Clin Oncol"},{"doi-asserted-by":"publisher","key":"e_1_2_5_51_1","DOI":"10.1056\/NEJMc1111010"},{"doi-asserted-by":"publisher","key":"e_1_2_5_52_1","DOI":"10.1182\/blood-2012-04-421883"},{"doi-asserted-by":"publisher","key":"e_1_2_5_53_1","DOI":"10.1038\/bcj.2013.19"}],"container-title":["International Journal of Laboratory Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fijlh.12205","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijlh.12205","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,24]],"date-time":"2023-09-24T16:17:13Z","timestamp":1695572233000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijlh.12205"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,3,27]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,12]]}},"alternative-id":["10.1111\/ijlh.12205"],"URL":"https:\/\/doi.org\/10.1111\/ijlh.12205","archive":["Portico"],"relation":{},"ISSN":["1751-5521","1751-553X"],"issn-type":[{"type":"print","value":"1751-5521"},{"type":"electronic","value":"1751-553X"}],"subject":[],"published":{"date-parts":[[2014,3,27]]},"assertion":[{"value":"2014-06-02","name":"published_online","label":"Published Online","group":{"name":"publication_history","label":"Publication History"}}]}}